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We performed a postmarketing surveillance study to determine the efficacy and safety 
of the oral quinolone antibacterial agent garenoxacin (Geninax® Tablets 200 mg) against 
atypical pneumonia. 
Between October 2009 and July 2011, patients with community-acquired pneumonia 
visited 26 facilities in Japan; we collected survey forms from 105 of these patients who 
were suspected of having atypical pneumonia based on the Japanese Respiratory Society 
Guidelines for the Management of Community-Acquired Pneumonia in Adults. We 
examined the safety in 105 patients and the efficacy in 71 patients. 
1. The efficacy rates among patients suspected of having atypical pneumonia and those 
with a confirmed diagnosis of atypical pneumonia were 94.8% (55/58 patients) and 
92.3% (12/13 patients), respectively. The efficacy rate was 4/4 for patients in whom 
Chlamydophila pneumoniae was detected (including 1 patient with a polymicrobial 
infection with another bacterial strain) and 90% (9/10 patients) for patients in whom 
Mycoplasma pneumoniae was detected (garenoxacin was ineffective in 1 of 2 patients 
with a polymicrobial infection with another bacterial strain). 
2. The incidence of adverse drug reactions (including abnormal laboratory tests) was 
4.8% (5/105 patients). Among the adverse drug reactions, gastrointestinal disorders, 
infection and infestation, nervous system disorder, and skin and subcutaneous tissue 
disorder were observed in 2.9% of patients (3/105), 1.0% (1/105), 1.0% (1/105), and 
1.0% (1/105), respectively. 
In conclusion, garenoxacin showed an efficacy rate of greater than 90% for suspected 
atypical pneumonia and confirmed atypical pneumonia. Garenoxacin is considered to be 
useful in daily practice. 
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Garenoxacin (GRNX) is an oral quinolone antibiotic manufactured by Toyama 
Chemical Co., Ltd. (Tokyo, Japan); the company obtained approval for manufacturing 
and marketing this medication in July 2007 under the product name Geninax® Tablets 
200 mg. GRNX has a novel and unique chemical structure with lack of fluorine atom at 
the 6-position of the quinolone skeleton, which is normally considered essential to the 
antibacterial activity of conventional fluoroquinolones. GRNX shows excellent 
antibacterial activity against major bacterial pathogens in respiratory and 
otorhinolaryngological infections by inhibiting type II topoisomerases (DNA gyrase and 
topoisomerase IV), which are involved in bacterial DNA replication. In addition, GRNX 
shows strong antibacterial activity against penicillin-resistant Streptococcus pneumoniae, 
the increasing prevalence of which in the recent years has become a cause of concern [1, 
2]. Further, because this drug shows a large AUC [3] and good tissue penetration [4, 5] 
after administration of a single dose of 400 mg/day, plasma concentrations in excess of 
the mutant prevention concentration for S. pneumoniae and Staphylococcus aureus were 
obtained for more than 24 h. Thus, GRNX is expected to prevent the emergence of 
drug-resistant strains [6]. Additionally, the antibacterial activity of GRNX against 
Chlamydophila pneumoniae and Mycoplasma pneumoniae associated with atypical 
pneumonia is stronger than that of existing fluoroquinolones and is comparable to that of 
macrolides [2]. 
The Phase II and Phase III clinical trials performed in Japan to investigate the clinical 
efficacy of GRNX on atypical pneumonia [7, 8] showed that the efficacy rates in 
mycoplasma pneumonia and chlamydia pneumonia were 100% (22/22 patients) and 
92.3% (12/13 patients), respectively. However, data on the efficacy of GRNX against 
these strains were not obtained from a sufficient number of patients at the time of 
development; therefore, active postmarketing data collection was indicated at the time of 
approval. 
In this study, we performed a specified postmarketing surveillance study to confirm 
the efficacy and safety of GRNX against atypical pneumonia in daily clinical practice. 
 
 
(2) Patients and methods 
 
(2)-1 Target patients 
3 
The subjects were patients treated at 26 medical institutions across Japan between 
October 2009 and July 2011 who met the following inclusion criteria and to whom the 
exclusion criteria did not apply (Table 1). 
The inclusion criteria were as follows: 
1. Patients who were 15 years old or older 
2. Patients who had a negative result in S. pneumoniae urinary antigen test 
3. Patients who were differentiated as having suspected atypical pneumonia (Table 
2) according to the Japanese Respiratory Society Guidelines for the Management 
of Community-Acquired Pneumonia in Adults (the JRS Guidelines) [9] 
Atypical pneumonia suspected 
Using criteria 1 to 5 on Table 2: in cases where at least 3 of 5 criteria are 
satisfied 
Using all the 6 criteria on Table 2: in cases where at least 4 of 6 criteria are 
satisfied 
4. Patients who had infiltrative shadows that thought to have appeared acutely and 
newly on chest radiographic images and not exceeding 2/3 of one lung 
5. Patients who had respiratory symptoms (e.g., cough, chest pain, or dyspnea) 
6. Patients who could ingest orally 
7. Patients who did not require a combination of other antibiotics or steroids when 
GRNX therapy was initiated (however, patients undergoing long-term treatment 
with a low-dose macrolide antibiotic at a fixed dose or patients receiving a drug 
with a prednisolone conversion of ≤30 mg/day at a fixed dose continued these 
regimens) 
8. Patients who took no other antibiotics within 7 days before initiation of GRNX 
therapy (however, patients in whom other antibiotics were considered to be 
ineffective and infection was detected were allowed) 
The exclusion criteria were as follows: 
1. Patients who had a history of hypersensitivity to GRNX or other quinolones 
2. Patients who were pregnant or possibly pregnant or were lactating 
3. Patients who previously enrolled in the study 
4. Patients in whom drug efficacy of GRNX was difficult to assess 




This study was performed as a prospective study using a central registration system. 
The patients were registered on the registration center until the day after the beginning of 
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GRNX. Informed consent and ethics committee approval were obtained as required for 
postmarketing surveillance. The survey items were as follows: patient characteristics 
(sex, age, inpatient/outpatient, weight, infectious disease diagnosis, severity of 
pneumonia [A-DROP scoring system], underlying diseases [diseases related to 
pneumonia], complications [diseases not related to pneumonia], hepatic function disorder 
before GRNX therapy, renal impairment before GRNX therapy, and history of adverse 
drug reactions or allergies); antibiotics taken immediately before (within 1 week) 
initiation of GRNX therapy; administration status of GRNX (dose, number of doses, and 
administration period); concomitant drugs; combination therapies; clinical symptoms and 
signs; laboratory tests; bacteriological examinations; rapid diagnosis and serological 
tests; clinical efficacy; and adverse events. Of rapid diagnosis and serological tests to 
determine the causative agents of pneumonia (Table 3), the S. pneumoniae urinary 
antigen test and microimmunofluorescence (micro-IF) testing of C. pneumoniae were 
performed. The micro-IF testing of C. pneumoniae was performed at the central 
laboratory. Other rapid diagnosis and serological tests were performed as required. 
GRNX was administered under the approved regimen, and the administration period, 
concomitant drugs and combination therapies were not limited. 
The observation period was until the termination of GRNX therapy. However, 
serological tests were adopted until 21 days after GRNX therapy for the termination of 
GRNX therapy. Adverse events were monitored until 4 days after GRNX therapy was 
terminated. 
 
(2)-3 Efficacy evaluation 
Clinical efficacy was assessed at the termination of GRNX therapy and was classified 
as “effective,” “ineffective,” or “evaluation not possible” according to clinical efficacy 
criteria [10] (Table 4). In patients receiving GRNX for 10 days or more, an additional 
assessment was made on the 10th day after initiation of GRNX. 
Safety was evaluated on the basis of the occurrence of adverse drug reactions. Adverse 
drug reactions were any events which a causal relationship with GRNX could not be 
denied during the observation period, such as medically unfavorable and unintended 
signs and symptoms (e.g., abnormal changes in laboratory tests and clinical symptoms 
and signs). Exacerbation of the pneumonia because of insufficient response to GRNX 
was not included. 
 
(2)-4 Assessment of judgment/totalization results 
An evaluation committee was formed with 5 members (one principal investigator, 
three coordinating investigators, and a representative physician), to discuss whether to 
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include the problem cases, the handling of data in cases that deviated from the protocol, 
the handling of bacterial pathogens, and causal relationship between adverse events and 
GRNX therapy. 
The term “bacterial pathogens” referred to bacteria that were detected at a score of 
≥3+ (the level of ≥105 colony-forming units/ml) derived from sputum. S. pneumoniae 
and Haemophilus influenzae detected at a clear level were classified as bacterial 
pathogens. Positive Mycoplasma pneumoniae rapid diagnosis results and positive C. 
pneumoniae and M. pneumoniae serological test results were also obtained to detect 
bacterial pathogens. 
Adverse drug reactions were analyzed using the Medical Dictionary for Regulatory 
Activities, Japanese version (MedDRA/J, ver. 15.0). 
 
(2)-5 Analysis sets 
Efficacy was evaluated in the patients in the efficacy analysis set, which included 
patients from whom survey forms were collected and who met the inclusion and 
exclusion criteria and who received GRNX under the approved regimen. The safety was 
evaluated in the patients in the safety analysis set from whom survey forms were 
collected and who received GRNX at least one time. 
 
(2)-6 Statistical analysis 
Statistical analysis was performed using χ2 test for comparison, and when the 





(3)-1 Analysis sets and patient characteristics 
The analysis sets are shown in Figure 1. 
Of the 105 patients from whom the survey forms were collected, all patients were 
included in the safety analysis set. From the safety analysis set, 71 patients were selected 
for the efficacy analysis set. From the efficacy analysis set, 21 patients were selected for 
the bacterial pathogens detection set. 
Table 5 shows the implementation status of bacteriological examination, rapid 
diagnosis and serological tests in 71 patients with suspected atypical pneumonia in the 
efficacy analysis set. The bacterial pathogens are shown in Figure 2. 
Of the 71 patients in whom efficacy analysis was performed, 14 had a confirmed 
diagnosis of atypical pneumonia, while 7 had bacterial pneumonia; in the remaining 50 
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patients, the bacterial pathogen could not be identified. Among 14 patients with a 
confirmed diagnosis of atypical pneumonia, 8 were infected with M. pneumoniae 
(ImmunoCard® [Meridian, USA], 5 patients; particle agglutination [PA], 2 patients; and 
complement fixation, 1 patient), 4 were infected with C. pneumoniae (enzyme-linked 
immunosorbent assay [ELISA], 3 patients; and enzyme immunoassay [Ani Labsystems, 
Finland], 1 patient), 1 had a mixed infection of M. pneumoniae and S. pneumoniae 
(identified by ImmunoCard® and bacterial culture, respectively), and 1 had a mixed 
infection of C. pneumoniae, M. pneumoniae, and Klebsiella pneumoniae (identified by 
ELISA, PA, and bacterial culture, respectively). None of the patients were positive for C. 
pneumoniae in micro-IF testing. None of the patients were positive for Legionella 
pneumophila in urinary antigen test. 
The patient characteristics of efficacy and safety analysis sets are shown in Table 6. 
Among patients in the safety analysis set, 61.0% were female, 84.8% were non-elderly, 
93.3% were outpatients, 87.6% had mild pneumonia according to the A-DROP scoring 
system, 87.6% had no underlying disease, and 84.8% were not receiving antibiotic 
treatment immediately before initiation of GRNX therapy. The average administration 
period was 8.4 ± 2.6 days, with the greatest number of patients at 3 to 7 days (51.4%), 
followed by 8 to 14 days (45.7%). Patient characteristics in the efficacy analysis set were 
almost same as those in the safety analysis set. 
 
(3)-2 Clinical efficacy 
In the efficacy analysis set (suspected atypical pneumonia), the clinical efficacy 
findings at the time of the termination and the 10th day of GRNX therapy are shown in 
Table 7. 
The efficacy rate of GRNX at the time of the termination of administration, excluding 
patients with an indeterminate result, was 94.8% (55/58 patients). The efficacy rate 
according to the severity of pneumonia using the A-DROP scoring system was 96.0% 
(48/50 patients) in those with mild pneumonia and 7/8 patients in those with moderate 
pneumonia. The efficacy rate according to the length of GRNX administration period 
was 89.5% (17/19 patients) for an administration period of 6–7 days, 100% (21/21 
patients) for 8–10 days, and 100% (10/10 patients) for 11–14 days, respectively. In 
addition, the efficacy rate in patients who received GRNX for 10 days or more and in 
whom clinical efficacy was evaluated at the 10th day after initiation of GRNX therapy 
was 100% (16/16 patients), which was similar to the efficacy rate at the termination of 
GRNX therapy. 
In the 10 patients who received antibiotic treatment prior to GRNX therapy (within 7 
days before beginning administration), for whom antibiotics were ineffective or 
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pneumonia recurred without the antibiotics taking effect, the efficacy rate of GRNX was 
100% (10/10 patients). The antibiotics taken before initiation of GRNX therapy were as 
follows: cefcapene pivoxil (CFPN-PI) in 4 patients; clarithromycin (CAM) in 3 patients; 
and cefditoren pivoxil (CDTR-PI), azithromycin, and levofloxacin (LVFX) in 1 patient 
each. All of these antibiotic treatments were oral medications. In these 10 patients, the 
prior antibiotic treatment was considered to be ineffective after 2 to 8 days of 
administration and they received GRNX. The bacterial pathogens were detected in 5 of 
10 patients: M. pneumoniae in 3 patients and H. influenzae in 2 patients. M. pneumoniae 
was detected in 3 patients who received CDTR-PI, CFPN-PI, or CAM. H. influenzae was 
detected in 2 patients who received CFPN-PI. 
The clinical efficacy in patients with a definitive diagnosis of atypical pneumonia is 
shown in Table 8. 
GRNX was effective in 8/8 patients with M. pneumoniae single-strain infection; 3/3 
patients with C. pneumoniae single-strain infection; 0/1 patient with a two-strain 
infection (mixed infection of M. pneumoniae and S. pneumoniae); and 1/1 patient with a 
three-strain infection (mixed infection of C. pneumoniae, M. pneumoniae, and K. 
pneumoniae). GRNX administration was effective in all patients, except 1 with a mixed 
infection of M. pneumoniae and S. pneumoniae. 
 
(3)-3 Adverse drug reactions 
Overall, 7 adverse drug reactions related with GRNX were observed in 5 non-elderly 
patients, and the incidence of adverse drug reaction was 4.8% (5/105 patients) (Table 9). 
Adverse drug reactions included upper abdominal pain in 1 patient, diarrhoea in 1 patient, 
rash in 1 patient, concurrent gastroenteritis and headache in 1 patient, and concurrent 
diarrhoea and vomiting in 1 patient. In the patient who presented with concurrent 
gastroenteritis and headache, GRNX therapy was discontinued; these symptoms 
disappeared 2–3 days after discontinuing GRNX therapy. No serious adverse drug 
reactions were observed. 
The incidences of adverse drug reactions according to the MedDRA/J system organ 
class were as follows: gastrointestinal disorders in 2.9% of patients (3 patients); 
infections and infestations in 1.0% (1 patient); nervous system disorders in 1.0% (1 
patient); and skin and subcutaneous tissue disorders in 1.0% (1 patient). 
 
(4) Discussion 
In the present study, we examined the usefulness of GRNX for treatment of atypical 
pneumonia in daily clinical practice. The clinical efficacy (efficacy rate) for 71 patients 
with suspected atypical pneumonia at the time of termination of GRNX therapy was 
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94.8% (55/58 patients). These patients included 14 patients with a definitive diagnosis of 
atypical pneumonia; the efficacy rate in these patients was 92.3% (12/13 patients). In this 
study, we found that the efficacy of GRNX when used in daily clinical practice was 
similar to those in other clinical studies [7, 8]. 
In this study, we made an effort to exclude patients with bacterial pneumonia by 
excluding patients with a positive result in the S. pneumoniae urinary antigen test at the 
initiation of GRNX therapy. However, patients in the efficacy analysis set included 8 
patients with a definitive diagnosis of bacterial pneumonia and 2 with a definitive 
diagnosis of mixed infection. The JRS Guidelines [9] state that in differentiation of 
disease types, a firm differentiation of atypical pneumonia alone is difficult. Our findings 
were consistent with those described in the above guidelines. 
The efficacy rate of GRNX was 100% (10/10 patients) in patients for whom treatment 
with oral antimicrobial agents (e.g., CFPN-PI, CAM, and CDTR-PI) within 1 week of 
GRNX therapy was ineffective (or in whom pneumonia recurred without the agents 
taking effect). This efficacy rate was comparable to that of 93.8% (45/48 patients) in 
patients who did not receive antibiotic treatment before GRNX therapy. Antimicrobial 
agents used before GRNX therapy included quinolones in 1 patient, macrolides in 4 
patients, and cephems in 5 patients. In 5 of these patients, M. pneumoniae and H. 
influenzae were detected as the causative agents. GRNX has potent antibacterial activity 
against M. pneumoniae (MIC90, 0.0313 μg/ml) and H. influenzae (MIC90, 0.05 μg/ml) [2]. 
We considered that the efficacy rate of GRNX in this study reflected the antibacterial 
activity. In patients for whom antibiotic treatment was ineffective, the efficacy of GRNX 
could be confirmed in clinical practice. 
Among patients with moderate pneumonia as assessed by the A-DROP scoring system, 
GRNX was effective in 7/8 patients. Of the 7 patients in whom GRNX was effective, 4 
were elderly patients aged 76–81 years. In addition, all 9 patients with underlying 
diseases had bronchial asthma, which is a chronic respiratory disease; GRNX was 
effective in all these 9 patients. Thus, GRNX can be effective even in patients suspected 
with atypical pneumonia who possess the above-mentioned characteristics that reduce the 
efficacy of GRNX. 
A postmarketing surveillance performed in Japan [11] on a single daily administration 
of 500 mg of LVFX, an orally administered quinolone antimicrobial agent (like GRNX), 
which is effective against M. pneumoniae and C. pneumoniae, showed that LVFX was 
effective against M. pneumoniae and C. pneumoniae in 2/2 patients and 9/9 patients, 
respectively. In addition, a specific postmarketing surveillance of CAM [12, 13], which 
is a macrolide antibiotic recommended as an empiric treatment for outpatients with 
suspected atypical pneumonia in the JRS Guidelines [9], showed that the efficacy rates in 
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patients infected with M. pneumoniae, C. pneumoniae, M. pneumoniae + C. pneumoniae, 
and those suspected with atypical pneumonia were 96.8% (153/158 patients), 92.9% 
(78/84), 98.3% (57/58), and 96.3% (105/109), respectively. Despite the small number of 
patients in our study, our results showed that GRNX had the same efficacy as that of 
LVFX and CAM. 
Of 8 patients diagnosed with M. pneumoniae single-strain infection, 5 were diagnosed 
by using ImmunoCard®. ImmunoCard® is widely used in daily clinical practice, because 
it is rapid and easy to use. The frequency of use of ImmunoCard® in this study reflected 
that in daily clinical practice. However, Beersma et al. pointed out that ImmunoCard® 
may be inaccurate for the detection of M. pneumoniae [14]. We should consider using 
ImmunoCard® in combination with paired serum specimens or other diagnostic 
techniques to make a definitive diagnosis of M. pneumoniae infection. 
GRNX was considered to be ineffective in 3 patients when the administration was 
terminated. One patient was an elderly person who was suspected of having mild atypical 
pneumonia. The patient had complicating cerebrovascular disorder sequelae, and showed 
mild chest radiograph shadows and marked coughing and inflammatory response 
(C-reactive protein [CRP] level, 4.26 mg/dl); however, the bacterial pathogen could not 
be identified. In this case, GRNX therapy may have been ineffective because of 
aspiration pneumonia due to cerebrovascular disorder sequelae. The second patient was 
an elderly patient with a moderate mixed infection of S. pneumoniae detected in a 
bacteriological examination and was positive for mycoplasma in rapid diagnosis before 
initiation of GRNX therapy. Although the fever and symptoms showed a tendency to 
improve on the third day of GRNX administration, the agent was changed in accordance 
with the patient’s wishes; therefore, GRNX was considered to be ineffective. The third 
patient’s condition was diagnosed as mild suspected atypical pneumonia before initiation 
of GRNX therapy. Fever, chest pain, and pleural effusion were observed. However, the 
bacterial pathogen could not be identified in rapid diagnosis, a bacteriological 
examination, or measurement of serum antibody titer. GRNX was considered to be 
ineffective because of a diagnosis of pyothorax on the 6th day of administration. 
GRNX was administered for 10 days or more in 18 patients in the efficacy analysis set. 
GRNX was considered to be effective in 16 of these patients on the 10th day after 
initiation of administration, and thus administration was continued. Further examination 
about appropriate administration duration was considered necessary to ascertain when 
administration should be discontinued. 
The incidence of adverse drug reactions was 4.8% (5/105 patients). No unique adverse 
reactions to GRNX were observed; therefore, the safety of GRNX was not viewed as a 
problem deserving special mention. 
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In conclusion, GRNX may be used in outpatient treatment in daily clinical practice not 
only in patients with mild to moderate atypical pneumonia caused by M. pneumoniae and 
C. pneumoniae infection but also in patients suspected of having atypical pneumonia in 
which the pathogen cannot be identified. Thus, further studies using a large number of 
patients should be performed in the future. 
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Table 1 List of the investigating medical institutions 
 
Tamaki Clinic    Okayama Health Foundation Hospital  
Minamiosawa Medical Plaza   Saka General Hospital   
Kamei Clinic for Respiratory Diseases    Kurashiki Daiichi Hospital   
Hosshoji Medical Clinic  Kurashiki Central Hospital   
Tokorozawa Central Hospital     Ohara General Hospital    
Ozaki Clinic      Tohoku Kosei Nenkin Hospital 
Inoue Clinic      Moriya Osamu Clinic    
Shimonoseki City Central Hospital    Matsuoka Clinic    
Kawahara Internal Medicine     Kawasaki Hospital, Kawasaki Medical School 
Hiroshima Prefectural Hospital     Japanese Red Cross Sendai Hospital  
Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital  Tottori Seikyo Hospital   
Takamatsu Municipal Hospital           
Ehime University Hospital          
Kochi Medical School Hospital          
Tohoku University Hospital                   
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Table 2 Differentiation between bacterial pneumonia and atypical pneumonia 
 
Items of differentiation 
1. Under 60 years of age 
2. No or minor underlying diseases 
3. Stubborn cough 
4. Poor chest auscultatory findings 
5. No sputum, or no identified etiological agent by rapid diagnosis 
6. A peripheral white blood cell count below 10,000/μl 
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Table 3 Rapid diagnosis and serological tests to determine the causative agents of pneumonia 
 
Category  Bacterial pathogen  Assay  Positive criteria 
Rapid diagnosis  Streptococcus pneumoniae  Urinary antigen test  + 
  Legionella pneumophila  Urinary antigen test  + 
  Mycoplasma pneumoniae  ImmunoCard® (Meridian, USA)  + 
Serological test  Chlamydophila pneumoniae  
micro-IF 
 IgM  IgG  IgA 
     ≥16 titer  ≥8 titer  − 
    ELISA  IgM (ID)  IgG (ID)  IgA (ID) 
     Single serum  ≥2.00  ≥3.00  ≥3.00 
     Pair serum  −   Increase ≥1.35   Increase ≥1.00 
    CF         
     Single serum      ≥32 titer     
     Pair serum  ≥ 4-fold of increase 
    
EIA (Ani Labsystems, Finland) 
 IgM (ID)  IgG (ID)  IgA (ID) 
     ≥1.0   ≥1.0   ≥1.0 
  Mycoplasma pneumoniae  PA       
     Single serum      ≥320 titer     
     Pair serum  ≥ 4-fold of increase 
    CF         
     Single serum      ≥64 titer     
        Pair serum  ≥ 4-fold of increase 
micro-IF microimmunofluorescence, ELISA enzyme-linked immunosorbent assay, ID index values, CF complement fixation, EIA enzyme 
immunoassay, PA particle agglutination 
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Table 4 Clinical efficacy criteria 
 
Evaluation  Evaluation criteria 
Effective 
 
Of the conditions (1) to (3) below, if the following items are met; condition (1) fulfills its condition; 
either condition (2) or (3) satisfies these conditions; and remaining condition does not lead to 
exacerbation, it is classified as “effective.” 
       
  (1) Improvement or disappearance of the symptoms and signs of pneumonia  
   A determination of maximum body temperature, cough, sputum (amount, properties), dyspnea, 
chest pain, or chest rales. 
    (a) Improvement in the symptoms and signs of 1 item or more.  
    (b) In cases of fever at the initiation of administration (or registered), the fever must improve. 
     If the fever declines after the initiation of administration (or registered), even if body 
temperature is 37.0°C or more, it will be treated as an improvement. 
  (2) If all abnormalities in chest X-ray shadows improve or disappear   
   Determined on the basis of the density and spread of the chest X-ray shadow.  
  (3) Improvement or disappearance of inflammation    
   No exacerbated items and if the following 2 items are met, “Improvements to 9000/μl or less of 
the peripheral blood white blood cell count” or “Decline from the highest value of CRP.” 
The change within the range of normal level is not considered. 
Ineffective  If the above criteria are not “effective,” the case is determined to be “ineffective.” 
Evaluation not possible  If it is not possible to determine either “effective” or “ineffective,” it is classified as “evaluation not possible.” 
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Table 5 Implementation status of bacteriological examination, rapid diagnosis and 
serological tests 
 
Category Bacterial pathogen 
Efficacy analysis set (n=71) 
Positive/Performed patients 
Rapid diagnosis Streptococcus pneumoniae 0/71 
 Legionella pneumophila 0/50 
 Mycoplasma pneumoniae 6/16 
Serological tests Chlamydophila pneumoniae 5/52 
 Mycoplasma pneumoniae 7/57 
Bacterial cultures Bacteria other than atypical pathogen 9/32 
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Table 6 Patient characteristics 
 
Item Category 
  Safety analysis set   Efficacy analysis set 
 n= (%)  n= (%) 
Number of patients for analysis   105     71   
Sex 
Male   41 (  39.0 )   26 (  36.6 ) 
Female  64 (  61.0 )  45 (  63.4 ) 
Age 
Non-elderly a   89 (  84.8 )   60 (  84.5 ) 
Elderly b  16 (  15.2 )  11 (  15.5 ) 
Mean   44.5   45.7 
Inpatient/Outpatient 
Inpatient   7 (   6.7 )   7 (   9.9 ) 
Outpatient  98 (  93.3 )  64 (  90.1 ) 
Weight (kg) Mean   55.83   55.33 
Severity of pneumonia c 
Mild   92 (  87.6 )   62 (  87.3 ) 
Moderate  13 (  12.4 )  9 (  12.7 ) 
Underlying diseases 
No   92 (  87.6 )   62 (  87.3 ) 
Yes  13 (  12.4 )  9 (  12.7 ) 
COPD  1 (   1.0 )  1 (   1.4 ) 
Bronchial asthma  12 (  11.4 )  9 (  12.7 ) 
Emphysema  1 (   1.0 )  0 (   0  ) 
Other  1 (   1.0 )  0 (   0  ) 
Complications Yes   29 (  27.6 )   20 (  28.2 ) 
Antibiotic taken immediately  
before the initiation of GRNX 
No   89 (  84.8 )   61 (  85.9 ) 
Yes  16 (  15.2 )  10 (  14.1 ) 
Maximum daily dosage (mg) Mean   400   400 
Administration period (days) 
3–7   54 (  51.4 )   35 (  49.3 ) 
8–14  48 (  45.7 )  33 (  46.5 ) 
15–21  3 (   2.9 )  3 (   4.2 ) 
Mean ± S.D.   8.4 ± 2.6   8.4 ± 2.7 
Concomitant drug 
No  8 (   7.6 )  3 (   4.2 ) 
Yes  96 (  91.4 )  67 (  94.4 ) 
Unknown  1 (   1.0 )  1 (   1.4 ) 
Combination Antibiotic 
No   103 (  98.1 )   70 (  98.6 ) 
Yes  2 (   1.9 )  1 (   1.4 ) 
COPD chronic obstructive pulmonary disease 
a <65 years of age 
b ≥65 years of age 
c A-DROP scoring system 
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Table 7 Clinical efficacy according to patient characteristics 
 
Item Category 
Termination of administration  10th day of administration 
n = E I ENP ER (%)  n = E I ENP ER (%) 
Number of patients for efficacy analysis  71 55 3 13 55/58 (94.8)  18 16 0 2 16/16 (100) 
Sex 
Male 26 17 1 8 17/18 (94.4)  5 5 0 0 5/5 
Female 45 38 2 5 38/40 (95.0)  13 11 0 2 11/11 (100) 
Age 
Non-elderly a 60 47 1 12 47/48 (97.9)  14 13 0 0 13/13 (100) 
Elderly b 11 8 2 1 8/10 (80.0)  4 3 0 2 3/3 
Inpatient/Outpatient 
Inpatient 7 6 1 0 6/7  2 2 0 0 2/2 
Outpatient 64 49 2 13 49/51 (96.1)  16 14 0 2 14/14 (100) 
Severity of pneumonia c 
Mild 62 48 2 12 48/50 (96.0)  15 14 0 1 14/14 (100) 
Moderate 9 7 1 1 7/8  3 2 0 1 2/2 
Underlying disease 
No 62 46 3 13 46/49 (93.9)  15 14 0 1 14/14 (100) 
Yes 9 9 0 0 9/9  3 2 0 1 2/2 
Complication 
No 51 39 1 11 39/40 (97.5)  11 10 0 1 10/10 (100) 
Yes 20 16 2 2 16/18 (88.9)  7 6 0 1 6/6 
Antibiotic taken immediately before the 
initiation of GRNX 
No 61 45 3 13 45/48 (93.8)  12 10 0 2 10/10 (100) 
Yes 10 d 10 0 0 10/10 (100)  6 6 0 0 6/6 
Concomitant drug 
No 3 2 1 0 2/3  1 1 0 0 1/1 
Yes 67 52 2 13 52/54 (96.3)  16 14 0 2 14/14 (100) 
Unknown 1 1 0 0 1/1  1 1 0 0 1/1 
Combination antibiotic 
No 70 55 3 12 55/58 (94.8)  18 16 0 2 16/16 (100) 
Yes 1 0 0 1 -  0 0 0 0 - 
Administration period (days) 
2–3 2 0 1 1 0/1  0 0 0 0 - 
4–5 4 4 0 0 4/4  0 0 0 0 - 
6–7 29 17 2 10 17/19 (89.5)  0 0 0 0 - 
8–10 23 21 0 2 21/21 (100)  7 7 0 0 7/7 
11–14 10 10 0 0 10/10 (100)  8 7 0 1 7/7 
15–21 3 3 0 0 3/3  3 2 0 1 2/2 
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E Effective, I Ineffective, ENP Evaluation not possible, ER Efficacy rate = (Number of patients considered as “Effective”) / (Number of 
patients considered as “Effective” and “Ineffective”) 
a <65 years of age 
b ≥65 years of age 
c A-DROP scoring system 
d cefcapene pivoxil, 4 patients; clarithromycin, 3 patients; cefditoren pivoxil, 1 patient; azithromycin, 1 patient; levofloxacin, 1 patient 
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Table 8 Clinical efficacy in patients with a definitive diagnosis of atypical pneumonia 
 
Bacterial pathogens 
Termination of administration 
n = E I ENP ER (%) 
Total 14 12 1 1 12/13 (92.3) 
Monomicrobial infection 12 11 0 1 11/11 (100) 
 Mycoplasma pneumoniae 8 8 0 0 8/8 
 Chlamydophila pneumoniae 4 3 0 1 3/3 
Polymicrobial infection 2 1 1 0 1/2 
 2 strains      
  Mycoplasma pneumoniae  
+ Streptococcus pneumoniae 
1 0 1 0 0/1 
 3 strains      
  Chlamydophila pneumoniae  
+ Mycoplasma pneumoniae  
+ Klebsiella pneumoniae 
1 1 0 0 1/1 
E Effective, I Ineffective, ENP Evaluation not possible, ER Efficacy rate = (Number of 
patients considered as “Effective”) / (Number of patients considered as “Effective” and 
“Ineffective”) 
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Table 9 Adverse drug reactions 
 
Category of adverse drug reactions 
 
Incidence (%) 




Number of patients with adverse drug reactions  5 (4.8) 
 Number of adverse drug reactions  7  
Infections and infestations  1 (1.0) 
 Gastroenteritis  1 (1.0) 
Nervous system disorders  1 (1.0) 
 Headache  1 (1.0) 
Gastrointestinal disorders  3 (2.9) 
 Abdominal pain upper  1 (1.0) 
 Diarrhoea  2 (1.9) 
 Vomiting  1 (1.0) 
Skin and subcutaneous tissue disorders  1 (1.0) 
  Rash  1 (1.0) 
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The number of patients for included or excluded each analysis set. 




The number of patients categorized by bacterial pathogens in the efficacy analysis set. 
These categories are atypical pneumonia, bacterial pneumonia, and bacterial pathogen 
indeterminate. 
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Figure 1. Analysis sets 
Survey form collected patients 105
Patients excluded from the safety analysis set 0
Safety analysis set 105
Patients excluded from the efficacy analysis set 34
Contraindication 1
Did not meet the inclusion criteria 11
Not evaluated for efficacy 22
Efficacy analysis set 71
Patients not detected bacterial pathogens 50
Indicated bacteria not detected by bacteriological 
examination/rapid diagnosis/serological test before the 
initiation of GRNX therapy
Inadequate score of bacteriological examination a
50
Bacterial pathogens detection set 21
a Excluding patients who were positive in the rapid diagnosis/serological test
Figure 2. Categorization of patients by bacterial pathogens in the efficacy analysis set 
Efficacy analysis set
(atypical pneumonia suspected) 71
Atypical pneumonia confirmed
(including 2 patients with mixed infection) 14 Bacterial pathogen indeterminate 50 Bacterial pneumonia confirmed 7
Atypical pneumonia
(including 2 patients with mixed infection) Bacterial pneumonia
Mycoplasma pneumoniae 8 Haemophilus influenzae 4
Chlamydophila pneumoniae 4 Streptococcus pneumoniae 3
Mycoplasma pneumoniae
+ Streptococcus pneumoniae 1
Chlamydophila pneumoniae
+ Mycoplasma pneumoniae
+ Klebsiella pneumoniae
1
